Publication date: September 2026 Source: ESMO Gastrointestinal Oncology, Volume 13, Part B Author(s): M. Ueno, K. Ikezawa, Y. Komatsu, H. Nagano, T. Hisano, T. Terashima, K. Nio, C. Morizane, S. Shimizu, M. Ozaka, H. Ohyama, T. Otsuru, K. Sudo, N. Mizuno, C. Daniel, L. Martín-Fernández, N. Amellal, K. Bernard, M. Sasaki
NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: results from an open-label, phase II study. // ESMO Gastrointestinal Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S2949819826000658?dgcid=rss_sd_all
NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: results from an open-label, phase II study. ESMO Gastrointestinal Oncology. https://www.sciencedirect.com/science/article/pii/S2949819826000658?dgcid=rss_sd_all
“NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: results from an open-label, phase II study.” ESMO Gastrointestinal Oncology.
@article{article44849,
title = {NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: results from an open-label, phase II study},
journal = {ESMO Gastrointestinal Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S2949819826000658?dgcid=rss_sd_all}
}